Prostate CancerPhase 3S1216NCT01809691
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
A Phase 3 study testing TAK-700 and Bicalutamide in people with Prostate Cancer, run by SWOG Cancer Research Network at 560 sites in United States.
Trial summary
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- TAK-700 and Bicalutamide
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,313 participants
- Where
- 560 sitesUnited States
- Study dates
- 8 Mar 2013to 9 Sep 2025
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical diagnosis of metastatic prostate cancer.
- Serum testosterone within institutional limits of normal.
- PSA ≥ 2 ng/mL within 90 days prior to initiation of androgen deprivation. therapy (for early induction) or prior to registration (for late induction).
- DEXA scan within 2 years prior to registration.
- ECG within 42 days prior to registration and QTc interval ≤ 460 msec.
- LVEF within 42 days prior to registration and within institutional limits of normal.
Show all 12Show fewer
- Adequate hepatic function as evidenced by bilirubin ≤ 2 x institutional upper limit of normal (ULN), SGOT (AST) and SGPT (ALT) ≤ 3 x institutional ULN, or ≤ 5 x institutional ULN if liver metastases are present.
- Adequate renal function as evidenced by calculated creatinine clearance ≥ 40 mL/min.
- Adequate hematologic function as evidenced by leukocytes ≥ 3,000/mcL, absolute neutrophil count (ANC) ≥ 1,500/mcL, hemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mcL.
- Zubrod performance status of 0 - 2. Zubrod performance status 3 will be allowed if from bone pain only.
- ≥ 18 years of age.
- Men of reproduction potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception or agree to abstain from intercourse while receiving treatment on this study and for at least 4 months after protocol treatment ends.
Who cannot join
- Known brain metastases.
- No more than 36 months of prior neoadjuvant and/or adjuvant hormonal therapy.
- ≥ 6 months since completion of androgen deprivation therapy.
- Prior or concurrent therapy with ketoconazole, aminoglutethimide or abiraterone acetate, or enzalutamide (MDV3100). Concurrent megestrol for hot flashes is allowed.
- Prior chemotherapy for treatment of metastatic prostate cancer. Prior chemotherapy in the neoadjuvant or adjuvant setting is allowed.
- ≥ 2 years since completion of chemotherapy in the neoadjuvant or adjuvant setting.
Show all 19Show fewer
- Concurrent use of experimental therapy is not allowed.
- ≥ 30 days since prior medical castration for metastatic prostate cancer.
- If method of castration is a LHRH agonist, the patient must be willing to continue the use of LHRH and add bicalutamide or TAK-700 during protocol treatment.
- If the patient was on an antiandrogen (e.g. bicalutamide, flutamide), the patient must be willing to switch over to bicalutamide or TAK-700 (according to randomization).
- Prior bilateral orchiectomy.
- Concurrent use of LHRH antagonists (e.g. Degarelix)
- Grade III/IV cardiac disease (as defined by the NYHA Criteria), thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia.
- Uncontrolled hypertension (defined as blood pressure > 160 mmHg systolic and > 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the Screening visit) despite appropriate medical therapy.
- Known human immunodeficiency virus (HIV)infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study.
- History of primary and secondary adrenal insufficiency.
- Hypersensitivity to TAK-700, to TAK-700 metabolites, to bicalutamide, or to LHRH agonists.
- Gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing oral medications.
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.
Trial locations and contacts
560 sites in 1 country.
300 sites in 1 country
United States300 sites
Hawaii Oncology Inc-Pali Momi
‘Aiea, Hawaii, 96701
Hickman Cancer Center
Adrian, Michigan, 49221
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
Lovelace Medical Center-Downtown
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Hematology Oncology Associates
Albuquerque, New Mexico, 87106
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Mission Hospital-Memorial Campus
Asheville, North Carolina, 28801
Sutter Auburn Faith Hospital
Auburn, California, 95602
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, 80045
Rush - Copley Medical Center
Aurora, Illinois, 60504
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, 93301
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Eastern Maine Medical Center
Bangor, Maine, 04401
Summa Barberton Hospital
Barberton, Ohio, 44203
Hematology/Oncology Clinic LLP
Baton Rouge, Louisiana, 70809
Ochsner Health Center-Summa
Baton Rouge, Louisiana, 70809
Bronson Battle Creek
Battle Creek, Michigan, 49017
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Sanford Clinic North-Bemidgi
Bemidji, Minnesota, 56601
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59102
Veterans Administration Medical Center - Birmingham
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
IU Health Bloomington
Bloomington, Indiana, 47403
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Boston Medical Center
Boston, Massachusetts, 02118
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, 02135
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Veteran Affairs New York Harbor Healthcare System-Brooklyn Campus
Brooklyn, New York, 11209
Veterans Affairs Western New York Health Care System-Buffalo
Buffalo, New York, 14215
Roswell Park Cancer Institute
Buffalo, New York, 14263
Highline Medical Center-Main Campus
Burien, Washington, 98166
Mills - Peninsula Hospitals
Burlingame, California, 94010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Illinois CancerCare-Canton
Canton, Illinois, 61520
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, 48188
Saint Joseph Mercy Canton Health Center
Canton, Michigan, 48188
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Centralia Oncology Clinic
Centralia, Illinois, 62801
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Roper Hospital
Charleston, South Carolina, 29401
Charleston Hematology Oncology Associates-Roper
Charleston, South Carolina, 29403
Charleston Hematology Oncology Associates PA-St. Francis
Charleston, South Carolina, 29414
Medical University of South Carolina
Charleston, South Carolina, 29425
West Virginia University Charleston
Charleston, West Virginia, 25304
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Mount Sinai Hospital Medical Center
Chicago, Illinois, 60608
Northwestern University
Chicago, Illinois, 60611
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Weiss Memorial Hospital
Chicago, Illinois, 60640
Presence Saint Joseph Hospital-Chicago
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
The Christ Hospital
Cincinnati, Ohio, 45219
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, 45219
Siteman Cancer Center - Saint Peters
City of Saint Peters, Missouri, 63376
MetroHealth Medical Center
Cleveland, Ohio, 44109
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
University of Missouri - Ellis Fischel
Columbia, Missouri, 65212
John B Amos Cancer Center
Columbus, Georgia, 31904
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Columbus NCI Community Oncology Research Program
Columbus, Ohio, 43215
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
Carolinas HealthCare System NorthEast
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
City of Hope Corona
Corona, California, 92879
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Barnes-Jewish West County Hospital
Creve Coeur, Missouri, 63141
Genesis Medical Center - East Campus
Davenport, Iowa, 52803
Sutter Davis Hospital
Davis, California, 95616
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Health Center
Dayton, Ohio, 45415
Dayton NCI Community Oncology Research Program
Dayton, Ohio, 45420
Veteran Affairs Medical Center
Dayton, Ohio, 45428
Atlanta VA Medical Center
Decatur, Georgia, 30033
Cancer Care Center of Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Porter Adventist Hospital
Denver, Colorado, 80210
Colorado Blood Cancer Institute
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program NCORP
Denver, Colorado, 80222
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Doylestown Hospital
Doylestown, Pennsylvania, 18901
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Mercy Medical Center
Durango, Colorado, 81301
Southwest Oncology PC
Durango, Colorado, 81301
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Veterans Adminstration New Jersey Health Care System
East Orange, New Jersey, 07018-1095
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, 14905
Comprehensive Cancer Care and Research Institute of Colorado LLC
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Providence Regional Cancer Partnership
Everett, Washington, 98201
Inova Fairfax Hospital
Falls Church, Virginia, 22042
Roger Maris Cancer Center
Fargo, North Dakota, 58122
Sanford Clinic North-Fargo
Fargo, North Dakota, 58122
Sanford Medical Center-Fargo
Fargo, North Dakota, 58122
Botsford General Hospital
Farmington, Michigan, 48334
Lake Region Healthcare Corporation-Cancer Care
Fergus Falls, Minnesota, 56537
Armes Family Cancer Center
Findlay, Ohio, 45840
Orion Cancer Care
Findlay, Ohio, 45840
Aurora Health Center-Fond du Lac
Fond du Lac, Wisconsin, 54937
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Kaiser Permanente-Fremont
Fremont, California, 94538
University Oncology Associates
Fresno, California, 93701
Kaiser Permanente
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia, 30501
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Saint Catherine Hospital
Garden City, Kansas, 67846
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Glens Falls Hospital
Glens Falls, New York, 12801
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Cancer Research Consortium of West Michigan NCORP
Grand Rapids, Michigan, 49503
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Heartland Cancer Center
Great Bend, Kansas, 67530
Saint Rose Ambulatory and Surgery Center
Great Bend, Kansas, 67530
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Saint Francis Hospital
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Saint Francis Cancer Center
Greenville, South Carolina, 29607
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Greenwich Hospital
Greenwich, Connecticut, 06830
Self Regional Healthcare
Greenwood, South Carolina, 29646
Rocky Mountain Cancer Centers-Greenwood Village
Greenwood Village, Colorado, 80111
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Hays Medical Center
Hays, Kansas, 67601
Hendersonville Hematology and Oncology at Pardee
Hendersonville, North Carolina, 28791
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Park Ridge Hospital Breast Health Center
Hendersonville, North Carolina, 28792
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
Hines Veterans Administration Hospital
Hines, Illinois, 60141
Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii, 96817
Hawaii Oncology Inc-Kuakini
Honolulu, Hawaii, 96817
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Tripler Army Medical Center
Honolulu, Hawaii, 96859
New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire, 03106
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
M D Anderson Cancer Center
Houston, Texas, 77030
Michael E DeBakey VA Medical Center
Houston, Texas, 77030
MD Anderson Regional Care Center-Katy
Houston, Texas, 77094
Edwards Comprehensive Cancer Center
Huntington, West Virginia, 25701
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Iowa City VA Healthcare System
Iowa City, Iowa, 52246
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
University of Mississippi Medical Center
Jackson, Mississippi, 39216
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin, 53038
Joliet Oncology-Hematology Associates Limited
Joliet, Illinois, 60435
Fowler Family Center for Cancer Care
Jonesboro, Arkansas, 72401
Mercy Hospital-Joplin
Joplin, Missouri, 64804
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Presence Saint Mary's Hospital
Kankakee, Illinois, 60901
University of Kansas Cancer Center-West
Kansas City, Kansas, 66112
University of Kansas Cancer Center
Kansas City, Kansas, 66160
Truman Medical Center
Kansas City, Missouri, 64108
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, 64128
The University of Kansas Cancer Center-South
Kansas City, Missouri, 64131
Research Medical Center
Kansas City, Missouri, 64132
The University of Kansas Cancer Center-North
Kansas City, Missouri, 64154
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Ochsner Medical Center Kenner
Kenner, Louisiana, 70065
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, 99336
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists PA
Kinston, North Carolina, 28501
Seattle Cancer Care Alliance at EvergreenHealth
Kirkland, Washington, 98034
University of Tennessee - Knoxville
Knoxville, Tennessee, 37920
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
UC San Diego Moores Cancer Center
La Jolla, California, 92093
LRGHealthcare-Lakes Region General Hospital
Laconia, New Hampshire, 03246
Marshfield Clinic - Ladysmith Center
Ladysmith, Wisconsin, 54848
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida, 33805
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Sparrow Hospital
Lansing, Michigan, 48912
Memorial Medical Center - Las Cruces
Las Cruces, New Mexico, 88011
Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada, 89106
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
The University of Kansas Cancer Center-Lee's Summit
Lee's Summit, Missouri, 64064
Beebe Medical Center
Lewes, Delaware, 19958
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Saint Rita's Medical Center
Lima, Ohio, 45801
Veteran's Administration Medical Center
Little Rock, Arkansas, 72205
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Littleton Adventist Hospital
Littleton, Colorado, 80122
Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Loma Linda Healthcare System
Loma Linda, California, 92357
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, 80501
Los Angeles County-USC Medical Center
Los Angeles, California, 90033
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
McKee Medical Center
Loveland, Colorado, 80539
Lynchburg Hematology-Oncology Clinic
Lynchburg, Virginia, 24501
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
Vince Lombardi Cancer Clinic-Marinette
Marinette, Wisconsin, 54143
Marshfield Clinic
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Memorial Hospital Of Martinsville
Martinsville, Virginia, 24115
Fremont - Rideout Cancer Center
Marysville, California, 95901
Mather Veteran Affairs Medical Center
Mather, California, 95655
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Loyola University Medical Center
Maywood, Illinois, 60153
About this study
Official title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
- Conditions
- Prostate Cancer
- Being tested
- TAK-700, Bicalutamide
- Keywords
- Prostate cancer, TAK-700, Bicalutamide, S1216, androgen therapy, Phase III
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TAK-700Drug
Also called Orteronel
300 mg, PO, twice daily
BicalutamideDrug
Also called Casodex
50 mg, PO, q daily
| Study group | Role | What they receive |
|---|---|---|
| ADT + TAK-700 | Experimental | LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.
TAK-700, 300 mg, PO, twice daily Receives: Drug: TAK-700 |
| ADT + Bicalutamide | Active comparator | LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.
Bicalutamide, 50 mg, PO, q daily Receives: Drug: Bicalutamide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Overall survival is defined as the time from random assignment to the date of death from any cause
Measured: Duration of treatment and follow-up until death or 9 years after study start
Secondary outcomes (4)
Progression Free Survival
Progression Free Survival (PFS) is defined as the time from random assignment to first documentation of PSA progression, radiologic progression, clinical progression, or death, whichever occurred first.
PSA progression is defined as a ≥25% increase AND and absolute increase of at last 2 ng/mL from the nadir PSA (or from baseline PSA if there was no drop in PSA after starting treatment).
Radiologic progression is defined as two or more new lesions on radionuclide bone scans.
Clinical progression is defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Measured: Duration of treatment and follow-up until death or 9 years after study start
PSA Response Rates
Prostate-specific antigen (PSA) response rates were divided into complete response (CR: PSA < 0.2 ng/mL), partial response (PR: PSA between 0.2 and 4.0 ng/mL), and no response (NR: PSA > 4.0 ng/mL) at a 7-month landmark after random assignment.
Measured: 7 months after randomization
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Only adverse events that are possibly, probably or definitely related to study drug are reported. Adverse events are graded using the Common Terminology Criteria for Adverse Events (CTCAE v4.0) where grade refers to the severity of the AE.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Measured: Duration of treatment and follow-up until death or 9 years after study start
Long-term Survival
Long-term survival is defined as the time from random assignment to the date of death from any cause
Measured: After 10 years of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2013 (estimated)
- Study start8 Mar 2013
- Primary completion8 Mar 2022
- Study completion9 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,313 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Neeraj Agarwal, M.D., Principal investigator, University of Utah
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01809691
- Sponsor's protocol ID
- S1216
- Other IDs
- SWOG-S1216, NCI-2012-02876
- Acronym
- S1216
- Status last verified
- Dec 2025
- First submitted
- 8 Mar 2013
- Last updated
- 31 Dec 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: https://swog.org/Visitors/Download/Policies/Policy43.pdf
Publications
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 Jul 1;7(7):e2419966. doi: 10.1001/jamanetworkopen.2024.19966.
PubMed 38980676Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024 Sep;27(3):566-570. doi: 10.1038/s41391-024-00813-3. Epub 2024 Feb 29.
PubMed 38424319Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, Agarwal N. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. JAMA Netw Open. 2023 Aug 1;6(8):e2326546. doi: 10.1001/jamanetworkopen.2023.26546.
PubMed 37526936Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 Oct 1;40(28):3301-3309. doi: 10.1200/JCO.21.02517. Epub 2022 Apr 21.
PubMed 35446628
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
- ClinicalTrials.gov ID
- NCT01809691
- Acronym / sponsor ID
- S1216 / S1216
- Conditions
- Prostate Cancer
- Keywords
- Prostate cancer, TAK-700, Bicalutamide, S1216, androgen therapy, Phase III
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,313 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)
- Study start
- 8 Mar 2013 (actual)
- Primary completion
- 8 Mar 2022 (actual)
- Study completion
- 9 Sep 2025 (actual)
- First posted
- 13 Mar 2013 (estimated)
- Results
- Posted 8 Sep 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ADT + TAK-700 | Experimental | Drug: TAK-700LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months. TAK-700, 300 mg, PO, twice daily |
| ADT + Bicalutamide | Active comparator | Drug: BicalutamideLHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months. Bicalutamide, 50 mg, PO, q daily |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Clinical diagnosis of metastatic prostate cancer.
- Serum testosterone within institutional limits of normal.
- PSA ≥ 2 ng/mL within 90 days prior to initiation of androgen deprivation. therapy (for early induction) or prior to registration (for late induction).
- DEXA scan within 2 years prior to registration.
- ECG within 42 days prior to registration and QTc interval ≤ 460 msec.
Key exclusion criteria (19 listed)
- Known brain metastases.
- No more than 36 months of prior neoadjuvant and/or adjuvant hormonal therapy.
- ≥ 6 months since completion of androgen deprivation therapy.
- Prior or concurrent therapy with ketoconazole, aminoglutethimide or abiraterone acetate, or enzalutamide (MDV3100). Concurrent megestrol for hot flashes is allowed.
- Prior chemotherapy for treatment of metastatic prostate cancer. Prior chemotherapy in the neoadjuvant or adjuvant setting is allowed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TAK-700Also: Orteronel300 mg, PO, twice daily | Drug | ADT + TAK-700 |
| BicalutamideAlso: Casodex50 mg, PO, q daily | Drug | ADT + Bicalutamide |
Primary outcome
Overall Survival
Time frame: Duration of treatment and follow-up until death or 9 years after study start
Overall survival is defined as the time from random assignment to the date of death from any cause
4 secondary outcomes
Progression Free Survival
Time frame: Duration of treatment and follow-up until death or 9 years after study start
PSA Response Rates
Time frame: 7 months after randomization
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Time frame: Duration of treatment and follow-up until death or 9 years after study start
Long-term Survival
Time frame: After 10 years of follow-up
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38980676Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 Jul 1;7(7):e2419966. doi: 10.1001/jamanetworkopen.2024.19966.
- Derived from this study: PubMed 38424319Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024 Sep;27(3):566-570. doi: 10.1038/s41391-024-00813-3. Epub 2024 Feb 29.
- Derived from this study: PubMed 37526936Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, Agarwal N. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. JAMA Netw Open. 2023 Aug 1;6(8):e2326546. doi: 10.1001/jamanetworkopen.2023.26546.
- Derived from this study: PubMed 35446628Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 Oct 1;40(28):3301-3309. doi: 10.1200/JCO.21.02517. Epub 2022 Apr 21.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. https://swog.org/Visitors/Download/Policies/Policy43.pdf
Related trials for Prostate Cancer
Not yet recruiting
Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial
Bladder Carcinoma, Prostate Carcinoma
RecruitingObservational study
Collection of Blood From Patients With Cancer
Prostate Cancer, Breast Cancer
Active, not recruitingObservational study
Agriculture Health Study
Prostate Cancer, Pesticide Exposures
Active, not recruitingPhase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Prostate Cancer
RecruitingObservational study
Collection of Blood From Patients With Prostate Cancer
Cancer Of Prostate, Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Neeraj Agarwal, M.D. principal investigator
University of Utah
560 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing TAK-700 and Bicalutamide in people with Prostate Cancer, run by SWOG Cancer Research Network at 560 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 560 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: Duration of treatment and follow-up until death or 9 years after study start). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01809691, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2025; AzTrials last refreshed its copy on 6 Nov 2026.